Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference
BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Year: 2023
Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference
BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
Oncotelic Launches PR Chatbot
AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the…
Oncotelic Launches PR Chatbot
AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the…
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023 Combined launch of…
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023 Combined launch of…
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in…
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in…
Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders…
Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders…
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response…
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response…
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism
This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime…
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism
This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime…
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care…
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care…
Verizon upgrades network for Columbia customers
Columbia, SC ranked in the Top 10 highest performing metro markets, according to recent testing…
Verizon upgrades network for Columbia customers
Columbia, SC ranked in the Top 10 highest performing metro markets, according to recent testing…